formally known as gpha

Same medicine. Same results.
Lower cost.

Statement by Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on a Balanced Trans-Pacific Partnership that Will Benefit Patients and Protect Jobs


Steve Arnoff 



“At this week’s meeting of the chief negotiators of the Trans-Pacific Partnership (TPP) in Ho Chi Minh City, Vietnam, the Generic Pharmaceutical Association (GPhA) and its member companies continue to engage with officials from the 12 TPP countries.

GPhA supports trade agreements that protect timely and cost-effective patient access to beneficial generic drugs and biosimilars, and that also respect the rights of innovators. Importantly, trade agreements should not constrain job growth in the U.S. by blocking or delaying exports of generic drugs to foreign markets. Any final agreement should support the U.S.-based generic industry and open foreign markets for generic products.

GPhA strongly objects to any provisions that could threaten competition including patent linkage and exclusivity periods for reference products that unnecessarily delay access to lower-cost generic medicines.

As negotiations on this important agreement continue, GPhA reiterates its call for a balanced TPP that will provide people around the world safe, affordable medicines and protect American jobs.”

About GPhA
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 84 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at Follow us on twitter: @gpha.